Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LYQEA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ILB-3101
|
|||||
| Synonyms |
ILB 3101; ILB-3101; ILB3101
Click to Show/Hide
|
|||||
| Organization |
Inno Lake Pharmaceutical (Hangzhou) Co., Ltd.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Eribulin
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
